Cu 2 O/CuVO 3 Nano‐Heterojunction as a Highly Active Therapeutic Catalyst for Aggravating Redox Dyshomeostasis of Neoplastic Cells
Advanced Materials · 2025-08 · 37 (33)
DOI: 10.1002/adma.202502407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2025-06. Verfasst von Weisheng Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Materials and Energy, Southwest University, Chongqing, 400715, China. Hauptthemen laut MEDLINE: Copper, Homeostasis, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Key Research and Development Project of Sichuan Provincial Science and Technology Plan, Open Research Project from Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, National Key Research and Development Program of China.
Abstract (Originalsprache)
Redox dyshomeostasis is both a hallmark and a vulnerability of cancer cells, offering multiple avenues for therapeutic intervention. Herein, a belt‐like nano‐heterojunction Cu 2 O/CuVO 3 (CVO) is developed as a potential redox dyshomeostasis inducer by exacerbating ROS levels and compromising antioxidant defense without the need of exogenous stimulations. Steady‐state analysis reveals that CVO exhibits extraordinary reaction velocity and catalytic efficiency ( V max = 2.32 µ m s −1 , K cat = 0.49 s −1 ) in the production of hydroxyl radicals (·OH). Likewise, density functional theory (DFT) calculations indicate that the superb charge‐transferring properties in the heterojunction structure and unique surface coverage rate of CVO primarily dominate the high‐efficient catalytic reactions. Noteworthy, CVO is capable of inducing mitochondria dysfunction by aggravating the cellular redox imbalance, thereby triggering multiple cell death pathways and generating synergistic effects. Transcriptomics analysis outcomes further demonstrate that CVO exerts significant and distinct effects on key biological processes in tumor cells, encompassing but not limited to canonical pathways such as apoptosis, ferroptosis, and cuprotosis. Both in vitro and in vivo studies demonstrate the pronounced tumor‐inhibitory efficacy of CVO, which paves a promising pathway for the development of novel nanocatalysts that effectively target cancer through the amplification of redox dyshomeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Materials and Energy, Southwest University, Chongqing, 400715, China.
- Yibin Academy of Southwest University, Yibin, 644005, China.
ORCID-Profile: Peng Xue
Förderung
- Key Research and Development Project of Sichuan Provincial Science and Technology Plan
- Open Research Project from Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment
- National Key Research and Development Program of China
- Shuangcheng Cooperative Agreement Research Grant of Yibin
- Scientific and Technological Research Program of Chongqing Municipal Education Commission
Zitieren
APA
Zhu, W., Wu, J., Kang, Y., & Xue, P. (2025). Cu 2 O/CuVO 3 Nano‐Heterojunction as a Highly Active Therapeutic Catalyst for Aggravating Redox Dyshomeostasis of Neoplastic Cells. Advanced Materials, 37(33). https://doi.org/10.1002/adma.202502407
Vancouver
Zhu W, Wu J, Kang Y, Xue P. Cu 2 O/CuVO 3 Nano‐Heterojunction as a Highly Active Therapeutic Catalyst for Aggravating Redox Dyshomeostasis of Neoplastic Cells. Advanced Materials. 2025;37(33). doi:10.1002/adma.202502407
BibTeX
@article{Zhu2025,
author = {Zhu, Weisheng and Wu, Junjie and Kang, Yuejun and Xue, Peng},
title = {Cu 2 O/CuVO 3 Nano‐Heterojunction as a Highly Active Therapeutic Catalyst for Aggravating Redox Dyshomeostasis of Neoplastic Cells},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {33},
doi = {10.1002/adma.202502407}
}
EUVIMED